Staging of Alzheimer's disease: past, present, and future perspectives
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is also a recognition that the recruitment of additional pathological processes, mediated by abnormal Aβ levels, namely inflammation and tauopathy, play important roles in contributing to the progression of the disease [4,13].”
From Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Research works printed but not linked: 81
- Gonnella, 1984, Staging of disease. A case-mix measurement, JAMA, 251, 637, 10.1001/jama.1984.03340290051021 · DOI · Paper page
- Markson, 1991, Clinical outcomes management and disease staging, Eval. Health Prof., 14, 201, 10.1177/016327879101400205 · DOI
- Amin, 2017, The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more 'personalized' approach to cancer staging, CA Cancer J. Clin., 67, 93
- Villemagne, 2013, Amyloid-β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study, Lancet Neurol., 12, 357, 10.1016/S1474-4422(13)70044-9 · DOI · Paper page
- McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Reisberg, 1982, The global deterioration scale for assessment of primary degenerative dementia, Am. J. Psychiatry, 139, 1136, 10.1176/ajp.139.9.1136 · DOI · Paper page
- van Harten, 2018, Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging, Neurology, 91, e300, 10.1212/WNL.0000000000005863 · DOI · Paper page
- Kryscio, 2014, Self-reported memory complaints: implications from a longitudinal cohort with autopsies, Neurology, 83, 1359, 10.1212/WNL.0000000000000856 · DOI · Paper page
- Del Tredici, 2020, To stage, or not to stage, Curr. Opin. Neurobiol., 61, 10, 10.1016/j.conb.2019.11.008 · DOI
- Braak, 1995, Staging of Alzheimer’s disease-related neurofibrillary changes, Neurobiol. Aging, 16, 271, 10.1016/0197-4580(95)00021-6 · DOI · Paper page
- Mirra, 1991, The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
- Abner, 2017, Outcomes after diagnosis of mild cognitive impairment in a large autopsy series, Ann. Neurol., 81, 549, 10.1002/ana.24903 · DOI
- Schneider, 2009, The neuropathology of probable Alzheimer disease and mild cognitive impairment, Ann. Neurol., 66, 200, 10.1002/ana.21706 · DOI · Paper page
- Sperling, 2014, The A4 study: stopping AD before symptoms begin?, Sci. Transl. Med., 6, 10.1126/scitranslmed.3007941 · DOI · Paper page
- Jack, 2019, Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia, JAMA, 321, 2316, 10.1001/jama.2019.7437 · DOI · Paper page
- Johnson, 2013, Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association, Alzheimers Dement., 54, 476
- Rabinovici, 2019, Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia, JAMA, 321, 1286, 10.1001/jama.2019.2000 · DOI · Paper page
- Therriault, 2021, Determining amyloid-β positivity using 18F-AZD4694 PET imaging, J. Nucl. Med., 62, 247, 10.2967/jnumed.120.245209 · DOI
- Altmann, 2015, Regional brain hypometabolism is unrelated to regional amyloid plaque burden, Brain, 138, 3734, 10.1093/brain/awv278 · DOI
- Sperling, 2020, Association of factors with elevated amyloid burden in clinically normal older individuals, JAMA Neurol., 77, 735, 10.1001/jamaneurol.2020.0387 · DOI · Paper page
- Jansen, 2015, Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis, JAMA, 313, 1924, 10.1001/jama.2015.4668 · DOI · Paper page
- Chiotis, 2018, Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia, Mol. Psychiatry, 23, 1666, 10.1038/mp.2017.108 · DOI
- Xia, 2017, Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease, JAMA Neurol., 74, 427, 10.1001/jamaneurol.2016.5755 · DOI · Paper page
- Therriault, 2021, Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia, Ann. Clin. Transl. Neurol., 8, 2083, 10.1002/acn3.51457 · DOI
- Pascoal, 2020, 18F-MK-6240 PET for early and late detection of neurofibrillary tangles, Brain, 143, 2818, 10.1093/brain/awaa180 · DOI · Paper page
- Therriault, 2020, Topographical distribution of amyloid-β, tau and atrophy in behavioral / dysexecutive AD patients, Neurology, 96, e81
- Scheltens, 2021, Alzheimer’s disease, Lancet, 397, 1577, 10.1016/S0140-6736(20)32205-4 · DOI · Paper page
- Fantoni, 2020, The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging, J. Nucl. Med., 61, 166, 10.2967/jnumed.119.235879 · DOI
- Pascoal, 2020, Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment, Alzheimers Dement., 12
- Collij, 2020, Multitracer model for staging cortical amyloid deposition using PET imaging, Neurology, 95, e1538, 10.1212/WNL.0000000000010256 · DOI · Paper page
- Lowe, 2018, Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia, Brain, 141, 271, 10.1093/brain/awx320 · DOI · Paper page
- Therriault, 2022, Biomarker modeling of Alzheimer’s disease using PET-based Braak staging, Nat. Aging., 10.1038/s43587-022-00204-0 · DOI · Paper page
- Franzmeier, 2020, Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease, Sci. Adv., 6, 10.1126/sciadv.abd1327 · DOI · Paper page
- Jacobs, 2018, Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals, Nat. Neurosci., 21, 424, 10.1038/s41593-018-0070-z · DOI · Paper page
- Pascoal, 2021, Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages, Brain, 144, 3517, 10.1093/brain/awab248 · DOI
- Vogel, 2020, Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease, Nat. Commun., 11, 2612, 10.1038/s41467-020-15701-2 · DOI · Paper page
- Vogel, 2022, Subtypes of Alzheimer’s disease: questions, controversy, and meaning, Trends Neurosci., 45, 342, 10.1016/j.tins.2022.02.001 · DOI
- Ossenkoppele, 2021, Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers, EMBO Mol. Med., 13, 10.15252/emmm.202114398 · DOI
- Barthélemy, 2020, A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease, Nat. Med., 26, 398, 10.1038/s41591-020-0781-z · DOI · Paper page
- Lantero-Rodriguez, 2021, P-tau235: a novel biomarker for staging preclinical Alzheimer’s disease, EMBO Mol. Med., 13, 10.15252/emmm.202115098 · DOI · Paper page
- Leuzy, 2021, Comparing the clinical utility and diagnostic performance of CSF p-Tau181, p-Tau217, and p-Tau231 assays, Neurology, 97, e1681, 10.1212/WNL.0000000000012727 · DOI · Paper page
- Ashton, 2021, Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology, Acta Neuropathol., 141, 709, 10.1007/s00401-021-02275-6 · DOI · Paper page
- Gauthier, 2020, Impact of p-tau181 and p-tau217 levels on enrolment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs, Expert. Rev. Neurother., 20, 1211, 10.1080/14737175.2020.1841637 · DOI
- Ashton, 2020, An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders, Nat. Rev. Neurol., 16, 265, 10.1038/s41582-020-0348-0 · DOI · Paper page
- Petersen, 2022, Are plasma markers for Alzheimer’s disease ready for clinical use? Nat, Aging, 2, 94
- Hansson, 2021, Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease, Ann. Clin. Transl. Neurol., 8, 259, 10.1002/acn3.51253 · DOI
- Ossenkoppele, 2018, Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders, JAMA, 320, 1151, 10.1001/jama.2018.12917 · DOI · Paper page
- Haeberlein, 2022, Two randomized Phase 3 studies of aducanumab in early Alzheimer’s disease, J. Prev. Alzheimer’s Dis., 9, 197, 10.14283/jpad.2022.30 · DOI · Paper page
- Hampel, 2021, Developing the ATX(N) classification for use across the Alzheimer disease continuum, Nat. Rev. Neurol., 17, 580, 10.1038/s41582-021-00520-w · DOI · Paper page
- Fan, 2017, An early and late peak in microglial activation in Alzheimer’s disease trajectory, Brain, 140, 792
- Souza, 2019, The astrocyte biochemistry, Semin. Cell Dev. Biol., 95, 142, 10.1016/j.semcdb.2019.04.002 · DOI
- Carter, 2019, Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease, Eur. J. Nucl. Med. Mol. Imaging, 46, 348, 10.1007/s00259-018-4217-7 · DOI
- Vilaplana, 2020, Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease, Neurology, 94, e2026, 10.1212/WNL.0000000000009405 · DOI
- Harada, 2021, 18F-SMBT-1: a selective and reversible PET tracer for monoamine oxidase-b imaging, J. Nucl. Med., 62, 253, 10.2967/jnumed.120.244400 · DOI
- Tyacke, 2018, Evaluation of 11C-BU99008, a positron emission tomography ligand for theimidazoline 2 binding site in human brain, J. Nucl. Med., 10, 1597, 10.2967/jnumed.118.208009 · DOI
- Calsolaro, 2021, Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load, Mol. Psychiatry, 26, 5848, 10.1038/s41380-021-01193-z · DOI
- Kumar, 2021, Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain, Mol. Psychiatry, 26, 5833, 10.1038/s41380-021-01101-5 · DOI · Paper page
- van der Weijden, 2021, Myelin quantification with MRI: a systematic review of accuracy and reproducibility, Neuroimage, 226, 10.1016/j.neuroimage.2020.117561 · DOI
- Power, 2018, Combined neuropathological pathways account for age-related risk of dementia, Ann. Neurol., 84, 10, 10.1002/ana.25246 · DOI · Paper page
- Eusebi, 2017, Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis, Mov. Disord., 32, 1389, 10.1002/mds.27110 · DOI · Paper page
- Zhou, 2015, The diagnostic and differential diagnosis utility of cerebrospinal fluid α-synuclein levels in Parkinson’s disease: a meta-analysis, Parkinsons. Dis., 2015
- Fayyad, 2019, Parkinson’s disease biomarkers based on α-synuclein, J. Neurochem., 150, 626, 10.1111/jnc.14809 · DOI
- Shi, 2010, Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease, Neurosci. Lett., 480, 78, 10.1016/j.neulet.2010.06.009 · DOI · Paper page
- Chang, 2016, Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer’s disease, Neurochem. Int., 97, 1, 10.1016/j.neuint.2016.04.012 · DOI
- Barbour, 2008, Red blood cells are the major source of alpha-synuclein in blood, Neurodegener. Dis., 5, 55, 10.1159/000112832 · DOI · Paper page
- Cairns, 2007, TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions, Am. J. Pathol., 171, 227, 10.2353/ajpath.2007.070182 · DOI · Paper page
- Chen-Plotkin, 2010, TAR DNA-binding protein 43 in neurodegenerative disease, Nat. Rev. Neurol., 6, 211, 10.1038/nrneurol.2010.18 · DOI · Paper page
- Josephs, 2008, Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype, Neurology, 70, 1850, 10.1212/01.wnl.0000304041.09418.b1 · DOI · Paper page
- Josephs, 2014, TDP-43 is a key player in the clinical features associated with Alzheimer’s disease, Acta Neuropathol., 127, 811, 10.1007/s00401-014-1269-z · DOI · Paper page
- Wilson, 2013, TDP-43 pathology, cognitive decline, and dementia in old age, JAMA Neurol., 70, 1418, 10.1001/jamaneurol.2013.3961 · DOI · Paper page
- Foulds, 2008, TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration, Acta Neuropathol., 116, 141, 10.1007/s00401-008-0389-8 · DOI · Paper page
- Williams, 2017, Blood-based oligomeric and other protein variant biomarkers to facilitate pre-symptomatic diagnosis and staging of Alzheimer’s disease, J. Alzheimers Dis., 58, 23, 10.3233/JAD-161116 · DOI
- Goossens, 2015, TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies, Acta Neuropathol. Commun., 3, 15, 10.1186/s40478-015-0195-1 · DOI
- Salloway, 2021, A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease, Nat. Med., 27, 1187, 10.1038/s41591-021-01369-8 · DOI · Paper page
- Tian Hui Kwan, 2020, Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials, Dement. Geriatr. Cogn. Disord., 3, 334, 10.1159/000511506 · DOI
- Levey, 2021, Progress with treatments for Alzheimer’s disease, N. Engl. J. Med., 384, 1762, 10.1056/NEJMe2103722 · DOI
- Morris, 2019, Assessment of racial disparities in biomarkers for Alzheimer disease, JAMA Neurol., 76, 264, 10.1001/jamaneurol.2018.4249 · DOI · Paper page
- Gauthier, 2006, Mild cognitive impairment, Lancet, 367, 1262, 10.1016/S0140-6736(06)68542-5 · DOI · Paper page
- Liang, 2021, Mortality rates in Alzheimer’s disease and non-Alzheimer’s dementias: a systematic review and meta-analysis, Lancet Heal. Longev., 2, e479, 10.1016/S2666-7568(21)00140-9 · DOI · Paper page
- Morris, 1993, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology, 43, 2412, 10.1212/WNL.43.11.2412-a · DOI · Paper page
- McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement., 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page
Cited by
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Therriault, J., Vermeiren, M., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Lussier, F. Z., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4485 · Cited by 272
Self-citationBasheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
“Remarkably, the density and stereotyped spatiotemporal distribution of this neuro fi brillary pathology consistently correlate with the degree of cognitive decline, memory impairment, and brain atrophy [8 – 13].”
BackgroundAPOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Self-citationWu, Y., Dong, J.-H., Dai, Y.-F., Zhu, M.-Z., Wang, M.-Y., Zhang, Y., Pan, Y.-D., Yuan, X.-R., Guo, Z.-X., Wang, C.-X., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.06.002 · Cited by 84
Metadata
- Authors
- Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P.
- ORCID
- Therriault, Joseph
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 28
- Issue
- 9
- Pages
- 726-741
- ISSN
- 1471-4914
- Cited by
- 113
- References
- 75
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Canadian Institutes of Health Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Staging of Alzheimer's disease: past, present, and future perspectives. https://app.cochat.ai/papers/10.1016/j.molmed.2022.05.008
- The paper
- Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022). Staging of Alzheimer's disease: past, present, and future perspectives. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2022.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.